AI-Driven Advances in Precision Oncology: Toward Optimizing Cancer Diagnostics and Personalized Treatment

Cancer remains one of the main global public health challenges, with rising incidence and mortality rates demanding more effective diagnostic and therapeutic approaches. Recent advances in artificial intelligence (AI) have positioned it as a transformative force in oncology, offering the ability to process vast and complex datasets that extend beyond human analytic capabilities. By integrating radiological, histopathological, genomic, and clinical data, AI enables more precise tumor characterization, including refined molecular classification, thereby improving risk stratification and facilitating individualized therapeutic decisions. In diagnostics, AI-driven image analysis platforms have demonstrated excellent performance, particularly in radiology and pathology. Prognostic algorithms are increasingly applied to predict survival, recurrence, and treatment response, while reinforcement learning models are being explored for dynamic radiotherapy and optimization of complex treatment regimens. Beyond direct patient care, AI is accelerating drug discovery and clinical trial design, reducing costs and timelines associated with translating novel therapies into clinical practice. Clinical decision support systems are gradually being integrated into practice, assisting physicians in managing the growing complexity of cancer care. Despite this progress, challenges such as data quality, interoperability, algorithmic bias, and the opacity of complex models limit widespread integration. Additionally, ethical and regulatory hurdles must be addressed to ensure that AI applications are safe, equitable, and clinically effective. Nevertheless, the trajectory of current research suggests that AI will play an increasingly important role in the evolution of precision oncology, complementing human expertise and improving patient outcomes.